However, we speculated that pre-activation of T cells by interleukin 2 (IL-2) in combination with anti-CD3/anti-CD28-coated beads and subsequent co-receptor-mediated cross-linkage to tumor cells could perhaps already be operative. The gene discussed is CD28; the disease is neoplasm.